Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3323248 | 0.78 | HSD11B1 (0.56) | HSD11B1CYP3A4KMT2AALDH1A1KDM4E | |
| SCHEMBL5370191 | 0.77 | HSD11B1 (0.49) | HSD11B1CYP3A4KMT2ALMNASMN1; SMN2 | |
| SCHEMBL1770092 | 0.75 | HSD11B1 (0.52) | HSD11B1KMT2AALDH1A1KDM4E | |
| SCHEMBL3321222 | 0.74 | HSD11B1 (0.53) | HSD11B1KMT2ALMNASMN1; SMN2NPC1 | |
| SCHEMBL6206228 | 0.73 | TSHR (0.51) | NPC1RAB9AALDH1A1 | |
| SCHEMBL3323351 | 0.72 | NPC1 (0.51) | HSD11B1KMT2ALMNASMN1; SMN2NPC1 | |
| SCHEMBL1478276 | 0.72 | F2 (0.51) | CYP3A4KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL3318119 | 0.71 | ALDH1A1 (0.52) | HSD11B1CYP3A4KMT2ALMNASMN1; SMN2 | |
| SCHEMBL3322001 | 0.70 | HSD11B1 (0.48) | HSD11B1CYP3A4KMT2ALMNAALDH1A1 | |
| SCHEMBL1770013 | 0.70 | HSD11B1 (0.50) | HSD11B1CYP3A4KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| EP-1861384-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100502-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | STERIX LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | HSD11B1 3/4885CYP3A4 72/4885KMT2A 3083/4885 |
| US-20100120789-A1 | Compound | NR0B2, NR0B1, NR4A1 | HSD11B1 73/4885CYP3A4 100/4885KMT2A 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.